BioSig Technologies Signs Agreement to Conduct Pre-Clinical Studies at UCLA

August 20, 2015 — BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of California at Los Angeles (UCLA) to conduct preclinical evaluation of BioSig's Pure EP System in a ventricular tachycardia (VT) model.

Pure EP is a proprietary technology platform designed to improve the fidelity of clinical signals available for electrophysiology (EP) procedures. It is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings. This helps provide clarity of data which may be used to guide the EP's in identifying ablation targets

Jason Bradfield, M.D., director of the specialized program for cardiovascular technology innovation of the UCLA Cardiac Arrhythmia Center, will be the principal investigator; the studies will focus on intracardiac and percutaneous epicardial mapping utilizing the Pure EP information system to explore the complex scar architecture that typically supports multiple morphologies of VT.

Kalyanam Shivkumar, M.D., director Cardiac Arrhythmia Center and EP Programs said, "Catheter ablation of ventricular tachycardia is perhaps one of the most complex challenges in interventional cardiology and new technologies are needed."

For more information: www.biosigtech.com